| __timestamp | ADMA Biologics, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 6620800000 |
| Thursday, January 1, 2015 | 6745968 | 6533000000 |
| Friday, January 1, 2016 | 8494742 | 6452000000 |
| Sunday, January 1, 2017 | 18092835 | 6588100000 |
| Monday, January 1, 2018 | 22502922 | 5975100000 |
| Tuesday, January 1, 2019 | 25910757 | 6213800000 |
| Wednesday, January 1, 2020 | 35050817 | 6121200000 |
| Friday, January 1, 2021 | 42896889 | 6431600000 |
| Saturday, January 1, 2022 | 52458024 | 6440400000 |
| Sunday, January 1, 2023 | 59020000 | 6941200000 |
| Monday, January 1, 2024 | 8593800000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company compared to ADMA Biologics, Inc. over the past decade. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking at approximately $6.94 billion in 2023, reflecting a strategic investment in marketing and administration. In contrast, ADMA Biologics, a smaller player, has seen its SG&A expenses grow by over 1,100%, from $4.8 million in 2014 to nearly $59 million in 2023. This dramatic rise underscores ADMA's aggressive expansion efforts. The data highlights the contrasting scales and growth strategies of these two companies, offering insights into their market positioning and operational priorities.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing Innovation Spending: Eli Lilly and Company and ADMA Biologics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Summit Therapeutics Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.